Preview Mode Links will not work in preview mode

ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

Jan 31, 2023

The drug treatments we use to manage atrial fibrillation don't change the progression in the disease.

Catheter ablation, even when performed in younger and healthier patients, modifies the disease trajectory and prevents progression.

In this interview, Jason G. Andrade MD, FRCPC and Christopher M. Kramer MD, FACC...


Jan 24, 2023

Although lipoprotein(a) is believed to play a causal role in atherogenesis, there are no approved therapies to help lower it. The OCEAN(a) DOSE study examined a drug specifically designed to lower lipoprotein(a) through RNA interference.

In this interview, Michelle L. O'Donoghue MD, MPH and Nanette Kass Wenger MD, MACC...


Jan 17, 2023

Patients with chronic kidney disease are at high risk of worsening kidney disease and cardiovascular events. Treatments that can slow down the worsening of kidney disease and reduce the need for dialysis and kidney transplants and the risk of cardiovascular events are potentially of great importance. While diabetes...


Jan 10, 2023

A new study examined a very common clinical question of which loop diuretic or water pill is better in patients living with heart failure - torsemide or furosemide? Prior studies suggested that torsemide might be better than furosemide but they had never been compared head-to-head in a large clinical trial.

The...


Dec 22, 2022

In this interview, Glenn A. Hirsch MD, MHS, FACC and Alison L. Bailey MD, FACC discuss Top Takeaways from 2022: General Cardiology.

Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to...